Patient with markedly elevated CA 19-9 not associated with malignancy

Southern Medical Journal

Volumn 99, Issue 3, 2006, Pages 306-308

  Lowe, Douglas ^a   Lee, Jeffrey ^a   Schade, Robert ^a   Chaudhary, Ayaz ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Carbohydrate antigen 19 9 (CA 19 9); Jaundice; Pancreatic cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; ESOMEPRAZOLE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; COMMON BILE DUCT; CONCENTRATION (PARAMETERS); DUODENUM ULCER; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; JAUNDICE; LABORATORY TEST; MALE; PANCREAS CARCINOMA; PHYSICAL EXAMINATION; PRURITUS; SPHINCTEROTOMY; TREATMENT FAILURE; ULCER HEALING; WEIGHT REDUCTION;

AGED; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGIOPANCREATOGRAPHY, MAGNETIC RESONANCE; CHOLANGITIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; JAUNDICE; MALE; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33645100958     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000202695.97123.2b     Document Type: Article

References (15)

1. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;84:350-355.
2. Gansauge S, Gansauge F, Beger HG. Molecular oncology in pancreatic cancer. J Mol Med 1996;74:313-320.
3. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-971.
4. Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53-55.
5. DelVillano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983;29:549-552.
6. Ritts RE Jr, DelVillano BC, Go VL, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using NCI serum bank. Int J Cancer 1984;33:339-345.
7. Ritts RE Jr, Nagorney DM, Jacobsen DJ, et al. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994;9:707-716.
8. Craxi A, Patti C, Aragona E. Serum CA 19-9 levels in patients with hepatocelluar carcinoma or cirrhosis. Ital J Gastroenterol 1985;17:288-289.
9. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223-1225.
10. Smanio T. Proposed nomenclature and classification of the human pancreatic ducts and duodenal papillae: study based on 200 post mortems. Int Surg 1969;52:125-141.
11. Stimec B, Bulajic M, Korneti V, et al. Ductal morphometry of ventral pancreas in pancreas divisum: comparison between clinical and anatomical results. Ital J Gastroenterol 1996;28:76-80.
12. Outtas O, Barthet M, De Troyer J, et al. [Pancreatic panniculitis with intraductal carcinoid tumor of pancreas divisum]. Ann Dermatol Venereol 2004;131:466-469.
13. Martin Fernandez J, Ratia T, Gutierrez A, et al. Intraductal pancreatic carcinoma associated with pancreas divisum. Rev Esp Enferm Dig 2003;95:358-363.
14. Hunerbein M, Ghadimi BM, Benhidjeb T, et al. A rare malformation of the pancreaticobiliary junction long common channel cholechochal cyst and pancreas divisum in a patient with pancreatic cancer. Hepato-gastroenterology 1999;46:1647-1649.
15. Lehman GA, Sherman S. Anatomy and clinical significance of pancreas divisum. In: Rose BD (ed), UpToDate, Wellesley, MA, 2004.